ArticleFrontiers in public health2026
Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Thrombopoietin receptor agonists (TPO-RAs) are standard second-line therapies for chronic immune thrombocytopenia (ITP). Given the introduction of domestic options like hetrombopag, a comparative economic evaluation is essential to inform reimbursement policies in China. This study assessed the cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for Chinese adults with chronic ITP. Methods: A hybrid model comprising a decision tree and a Markov process was developed to simulate lifetime costs and health outcomes from the perspective of the Chinese healthcare system. Clinical efficacy parameters were derived from randomized controlled trials and a network meta-analysis (NMA). Utilities and costs were estimated using published literature and local data, respectively. Future costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. The primary outcome was the incremental net monetary benefit (iNMB) at a willingness-to-pay (WTP) threshold of CNY 287,391/QALY. Deterministic and probabilistic sensitivity analyses were performed to evaluate uncertainty. Results: Over a lifetime horizon, hetrombopag was the lowest-cost strategy (CNY 2,205,717), followed by eltrombopag (CNY 2,214,322) and avatrombopag (CNY 2,379,335). Although avatrombopag yielded the highest QALYs (10.449), hetrombopag (10.335 QALYs) dominated eltrombopag (10.159 QALYs) by providing greater health benefits at lower costs. Compared with avatrombopag, hetrombopag generated a positive iNMB of CNY 140,864, as the substantial cost savings outweighed the marginal reduction in QALYs. Probabilistic sensitivity analysis indicated that hetrombopag had the highest probability of being cost-effective across standard WTP thresholds. Conclusion: Under current pricing, hetrombopag represents the most cost-effective second-line TPO-RA for adult chronic ITP in China. It dominates eltrombopag and offers a favorable economic profile compared with avatrombopag. These findings support the use of hetrombopag as a preferred option in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.